Medical Patent News

RSS

Proteus receives U.S. patent for ingestible digital devices

Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the United States Patent Office awarded U.S. Patent Number 7,978,064 to Proteus.

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

AHF applauds Gilead for licensing AIDS drugs to Medicines Patent Pool

AIDS Healthcare Foundation (AHF) today lauded Gilead Sciences for being the first major AIDS drug company to share some drug patents with a new international Medicines Patent Pool, a move that will help ensure access to newer AIDS treatments in developing countries.

13 Jul 2011

Gilead becomes first company to license drugs to Medicines Patent Pool

"In the first agreement between a pharmaceutical company and the new international Medicines Patent Pool, Gilead Sciences announced Tuesday that it would license four of its AIDS and hepatitis B drugs to the pool," the New York Times reports.

13 Jul 2011

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Aeterna Zentaris Inc. today announced that the European Patent Office has granted a patent for the use of alkyl phosphocholines, more specifically perifosine, in the preparation of a medicament for the treatment of benign and malignant tumours, prior to and/or during the treatment with approved anti-tumour anti-metabolites such as 5FU and capecitabine.

12 Jul 2011

BioAlliance receives European patent for Livatag to treat primary liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces the grant of a European patent protecting its Transdrug nanotechnology.

12 Jul 2011

USPTO issues notice of allowance to PROLOR Biotech's CTP platform

PROLOR Biotech, Inc., today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins.

11 Jul 2011

German Court announces negative decision regarding validity of Aerocrine patent

Aerocrine AB today announced a negative decision by the Munich Court regarding the validity of one German Aerocrine patent. This decision does not influence Medisoft's obligation to respect the existing three courts decisions in Germany.

8 Jul 2011

LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

LFB announced today that it has been recently issued U.S. Patent 7,931,895 titled "Monoclonal Antibodies with Enhanced ADCC Function" on April 26, 2011, by the U.S. Patent and Trademark Office.

8 Jul 2011

U.S. District Court rules in favor of Watson over Mucinex patent suit

Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the Southern District of Florida's February 2011 decision that Watson's generic versions of Mucinex(R), Mucinex(R) D, and Mucinex(R) DM Extended-Release products do not infringe U.S. Patent No. 6,372,252.

8 Jul 2011

USPTO awards patent for key therapeutic ingredient in CNVN202 targeted molecular cancer therapy

Convergen LifeSciences, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.

29 Jun 2011

USPTO issues Notice of Allowance for Neurocrine's NBI-98854 to treat tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, NBI-98854.

24 Jun 2011

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset, Inc. announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 titled "Nucleoside Phosphoramidate Prodrugs".

22 Jun 2011

Supreme Court accepts case that could shape field of personalized medicine

The U.S. Supreme Court, accepting a case that will shape the burgeoning business of personalized medicine, agreed to consider what types of diagnostic medical tests can be patented. The justices agreed today to hear an appeal from the Mayo Clinic, which is challenging a lower court decision backing two patents for determining the dosage of medicines to treat stomach diseases.

22 Jun 2011

Two NJIT researchers receive U.S. Patent for nanoprobe array technique

Reginald C. Farrow and Zafer Iqbal, research professors at NJIT, were awarded a patent today for an improved method of fabricating arrays of nanoscale electrical probes. Their discovery may lead to improved diagnostic tools for measuring the spatial variation of electrical activity inside biological cells.

22 Jun 2011

ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license.

22 Jun 2011

Palatin receives U.S. patent titled ‘Amino Acid Surrogates for Peptidic Constructs'

Palatin Technologies, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs."

22 Jun 2011

AusBiotech supports ‘Raising the Bar’

AusBiotech welcomes a legislative Bill that has been introduced into the Australian Parliament today - The Intellectual Property Laws Amendment (Raising the Bar) Bill 2011.

21 Jun 2011

European Patent Office issues notice of allowance to Kuros' synthetic biomaterials

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today the allowance of European Patent Application 00910049 by the European Patent Office.

20 Jun 2011

Watson Pharmaceuticals confirms SEASONIQUE patent challenge

Watson Pharmaceuticals, Inc., a leading integrated global pharmaceutical company, today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE and ethinyl estradiol.

18 Jun 2011